Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Up 465.6% in April

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 495,062 shares, a growth of 465.6% from the March 31st total of 87,521 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 527,925 shares, the short-interest ratio is currently 0.9 days.

Sysmex Trading Up 1.5%

Shares of SSMXY stock opened at $8.71 on Friday. Sysmex has a 1-year low of $8.15 and a 1-year high of $19.39. The company has a market cap of $5.48 billion, a price-to-earnings ratio of 18.15 and a beta of 1.13. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. The stock has a 50 day simple moving average of $8.82 and a 200-day simple moving average of $9.74.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. The company had revenue of $837.32 million during the quarter, compared to analyst estimates of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. On average, equities research analysts expect that Sysmex will post 0.44 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Citigroup cut Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Sysmex presently has a consensus rating of “Hold”.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.